Online Tools

Print    Email
Decrease (-) Restore Default Increase (+) font size

Specific clinical trials available at Moses Cone Regional Cancer Center

 

Clinical trials currently under way
at Moses Cone Health System Regional
Cancer Center include:

For more information on clinical trials

 

Brain

Primary Brain Tumor

Brain Metastases

 

Breast

Adjuvant

NSABP B-43 - A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Beth CIRG 011 - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

ECOG 5103 - A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.

CALGB 40101 - Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycls) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Noves: A 2x2 Factorial Phasse III Randomized Study

Adjuvant or Hormone

LCCC 0801 - Evaluating the Role of Genotype in Tamoxifen Therapy for Breast Cancer. Contact the Clinical Research Office at (336) 832-0821 for more information.

CTSU ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx TrialVirgo AVF 4349n - An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer. Contact the Clinical Research Office at (336) 832-0821 for more information.

Cancer Control, Non Treatment

Virgo AVF 4349n - An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer. Contact the Clinical Research Office at (336) 832-0821 for more information.

Fatigue

Neoadjuvant

NSABP B-41 - A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.

Metastatic

CALGB 40502 - A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

CALGB 40503 - Endocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Traial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab for Women with Hormone Receptor-Positive Advanced Breast Cancer

LPT111110 - A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ERBB2 Overexpressing Metastatic Breast Cancer.

Hormone

IBCSG 25-02 - Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women with Endocrine-Responsive Breast Cancer

 

Cancer Control 

Non Treatment

CCCWFU 97106 - A Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors. Reopened for Minorities

Cervix

GOG 0240 - A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplie Bevacizumab versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix.

Endometrial

GOG 0210 - A Molecular Staging Study of Endometrial Cancer.

 

Gastrointestinal

Anal Canal

Colon, Metastatic

CALGB 80405 - A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.

Colon, Metastatic/Locally Advanced

LCCC 0918 - Multicenter study investigating utilization of pharmacokinetic-guided 5-Flourouracil in patients receiving mFOLFOX6 with or without bevacizumab. Contact the Clinical Research Office at (336) 832-0821 for more information.

Colon, Adjuvant

LCCC 0918 - Multicenter study investigating utilization of pharmacokinetic-guided 5-Flourouracil in patients receiving mFOLFOX6 with or without bevacizumab. Contact the Clinical Research Office at (336) 832-0821 for more information.

CTSU ECOG E5202 - A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

Non-Treatment

Esophagus

Esophagus, Metastatic

GIST

Pancreas, Metastatic

SWOG S0727 - A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer.

Rectal, Neoadjuvant

Rectal, Metastatic

CALGB 80405 - A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.

  

Genito-Urinary

Prostate, Hormone Refractory

Renal 

Multiple GU Sites

CALGB 90601 - A Radomized Double-Blinded Phase II study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Trasitional Cell Carcinoma.

Head and Neck

Oral Cavity, Oropharynx, Hypopharynx, Larynx

CTSU ECOG E1305 - A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

Leukemia

CLL

CALGB 10404 - A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

 

Lung

Metastatic

Abbott M10-301 - A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC as First-Line Treatment

SWOG S0709 - A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin Paclitaxel Erlotinib or Erlotinib Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 Selected by Serum Proteomics

CALGB 30704 - A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NCS#736511, IND #74019) or Pemetrexed plus Sunitinib in the Second-line Treatment of Advanced Non-small Cell Lung Cancer

CALGB 30607 - Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung

SWOG S0636 - A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC AdenocarcinomasNon-Small Cell, Advanced

Non-Small Cell, Advanced

Neoadjuvant/Adjuvant

Neoadjuvant

Non-Treatment

Adjuvant

SWOG S0720 - Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

CTSU ECOG 1505 - A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC).

Small Cell

SWOG S0802 - A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Afibercept, NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cance r(E-SCLC).

Chemoprevention

SWOG S0424 - Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men.

Lymphoma

 

Melanoma

CTSU ECOG 1697 - Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b No, T3a-bN0, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma

Multiple Myeloma

 

Non-Treatment

Nutrition

Ovarian

GOG 0252 - A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied.

GOG 0213 - A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (Nsc#704865, Ind #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer

GOG 0212 - A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel of Zyotax (CT-2103) (IND# 70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.

Uterine

 

 

 

Health Resources

Related Topics